Background: Lack of medication adherence is associated with significant morbidity and mortality, particularly among minorities. We aim to identify predictors of nonadherence to antiplatelet medications at the time of percutaneous coronary intervention (PCI) with stent among African American and Hispanic patients. Methods: We used data collected for a randomized clinical trial that recruited 452 minority patients from a large US health insurance organization in 2010 post-PCI to compare telephone-based motivational interviewing by trained nurses with an educational video. The primary outcome was 12-month adherence to antiplatelet medications measured by the claims-based medication possession ratio (MPR). Adequate adherence was defined as an MPR of 0.80 or higher. Results: More than half of the sample (age, 69.52 T 8.8 years) was male (57%) and Hispanic (57%). Most (78%) had a median income below $30 000 and 22% completed high school or higher. Univariate analyses revealed that symptoms of depression (G.01) and not having a spouse (P = .03) were associated with inadequate adherence. In multivariate analysis, baseline self-reported adherence (1.4; 95% confidence interval [CI], 1.05Y1.89), depressive symptoms (0.49; 95% CI, 0.7Y0.90), comorbidity (0.89; 95% CI, 0.80Y0.98), and telephone-based motivational interviewing by trained nurses (3.5; 95% CI, 1.9Y2.70) were associated with adherence. Conclusions: Having multiple comorbidities, depression, suboptimal adherence to medications, and low English proficiency at the time of PCI increase the risk of poor 12-month adherence to antiplatelets among minorities. Identifying these risk factors can guide PCI therapy and the use of evidence-based strategies to improve long-term adherence.
L arge-scale clinical trials have shown that the appropriate use of thienopyridines after percutaneous coronary intervention (PCI) with stent placement reduces the rates of death and myocardial infarction by about 57% 1 and the risk of in stent thrombosis by 88%. 2 Thus, current practice guidelines recommend that all patients undergoing PCI, over 1 million per year, 3 should be treated with thienopyridines for 3 to 12 months depending on the type of stent placed 4 to prevent complications. Unfortunately, the translation of this finding to everyday practice has been limited and only 50% to 75% of PCI patients are adherent to thienopyridines post stent placement.
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Inadequate adherence to medications is a pervasive healthcare problem that increases the risk of preventable hospitalizations, morbidity, and mortality. 8 Minorities have even lower adherence to chronic medications, 9 ,10 a finding that might explain the increased risk of adverse outcomes observed among African American and Hispanic patients after stent placement as well as the decreased probability of receiving drug eluting stents. 11, 12 Current guidelines recommend avoiding drug-eluting stents, a device with proven clinical superiority 13, 14 among patients with barriers to comply to 12 months of dual antiplatelet therapy. 15 In this context, it is imperative to identify those at risk of antiplatelet medication nonadherence at the time of stent placement. Even though modifying health behaviors such as adherence remains challenging, 16 in recent years, a few interventions have been successful in experimental design. 7, 17 Some of the successful interventions are those using patient-centered, directive approaches such as motivational interviewing. 7 Motivational interviewing has been shown to be effective in improving medication adherence among African Americans. 18 Learning how to identify patients at risk of nonadherence at the time of coronary stent placement is important to use an informed approach to select appropriate therapy and disseminate successful preventive strategies that can improve medication adherence.
The current study is a secondary data analysis of data collected during the conduction of a randomized control trial (RCT). The parent trial evaluated the efficacy of telephone-based motivational interviewing at improving adherence to antiplatelet medications among African American and Hispanic patients who underwent PCI. The objective of the secondary analysis was 2-fold: (1) identify predictors of nonadherence to antiplatelet medications that can be measured at the time of PCI among African American and Hispanic patients and (2) evaluate if telephone-based motivational interviewing, the intervention we previously reported to improve adherence in the RCT, 7 was equally effective among participants at higher risk of nonadherence.
Methods

Study Design
The current study is a retrospective cohort study of the parent RCT data. We conducted secondary analysis of all the data collected for all participants of both arms of the RCT: (1) a telephone-based motivational interview delivered by trained nurses (MINT) or (2) a mailed educational DVD. The details of the RCT have been previously reported. 7 Participants of the RCT completed a baseline and final survey (12 months post PCI) that collected social determinants of health, self-reported adherence, and barriers to adherence. The University of Miami Institutional Review Board approved all study procedures and materials
Study Patients
For this cohort study, we included the 452 African American and Hispanic participants of the RCT. To be included in the RCT, patients should have (1) been identified as African American or Hispanic, (2) been older than 18 years of age, (3) have received a coronary stent placement in the previous 90 days, and (4) have filled at least 1 prescription for clopidogrel or prasugrel within that timeframe. All the participants were recruited from a Humana Inc administrative claims database of approximately 3.5 million members throughout the United States enrolled in a commercial health maintenance organization, preferred-provider organization, or Medicaid/Medicare plan.
Predictors of Adherence
During the baseline survey, we collected a number of covariates considered social determinants of health, measurement variables derived from the concepts within theoretical frameworks or variables previously identified as predictors of adherence in other populations. 17, 19 Specifically, the following was collected.
Demographic Variables
Data on age, gender, marital status, self-reported income, self-reported education level, and insurance type were taking.
Race/Ethnicity
African American race and Hispanic ethnicity were identified using a validated 3-step algorithm based on (1) 23Y25 was used to collect self-reported medication adherence at baseline and at 12-months.
Comorbidity Burden
A validated Charlson comorbidity score 26, 27 was derived from administrative data to measure burden of disease. In the parent RCT, we searched the 9 fields present in the Humana administrative medical file for the International Classification of Diseases, Ninth Revision, codes that inform the Charlson comorbidity score.
Depressive Symptoms
We administered the 9-item Patient Health Questionnaire (PHQ9) 28 to determine the relationship between severity of depressive symptoms and medication adherence. The predictive ability of this instrument and of the 2-item Patient Health Questionnaire, which constitutes a validated depression screening instrument was separately evaluated.
Randomized Arm
The randomized arm (MINT or DVD) was considered a possible predictor of medication adherence. Briefly, MINT is a patient-centered strategy that was selected as the test intervention given its focus on self-determination and self-management as key mediators of successful behavior change. 29 The DVD arm of the trial was considered the control group and consisted of a 1-time mailed educational DVD designed by the authors. The DVD featured a physician providing poststent information and a patient modeling the desired behavior and discussing their experiences with the disease and stent procedure. All participants received care as usual from their healthcare providers that was independent of the RCT.
Other
Other domains we evaluated were access to care, beliefs regarding the medication, patient-physician communication, and trust.
Primary Outcome
The primary outcome of the original RCT and of this secondary analyses was adherence to antiplatelet medication measured thorough the medication possession ratio (MPR) for clopidogrel or prasugrel. The MPR is defined as the sum of the days" supply of medication divided by the number of days between the first fill and the last refill plus the days" supply of the last refill.
The MPR was calculated as a continuous variable from real time Humana claims pharmacy data using the validated formula below. 30 
MPR ¼~D
ays" supply of medicatioñ Number of days between the first fill and the last refill þ Days" supply of the last refill An MPR less than 1.0 is indicative of a lapse in prescription refilling/adherence. A more clinically meaningful interpretation of MPR is based on the dichotomized form, which was defined as an MPR of 0.80 or higher (adequate adherence or drug availability during Q80% of the therapy time) and MPR lower than 0.80 (nonadherence or drug availability during G 80% of the therapy time). Data regarding the dates of each clopidogrel or prasugrel prescription filled and the number of days supplied each time was captured 6 months after patients completed the study to calculate the MPR.
Statistical Analysis
#
2 Analyses were conducted to describe baseline characteristics such as gender, race/ethnicity, English language proficiency, marital status, self-reported income, self-reported education level, insurance type, low health literacy, positive screening of depressive symptoms (2-item Patient Health Questionnaire) or moderate to severe depressive symptoms (PHQ-9), presence of diabetes, previous myocardial infarction, and congestive heart failure. t Tests were conducted to compare age, the Charlson comorbidity score, and the MMAS-4 score. Similar methodologies were used to compare groups according to patients race/ethnicity and gender. A P value of less than or equal to .05 was considered statistically significant.
Univariate and multivariate linear and logistic regression models were developed to identify possible predictors of adherence using the continuous and the categorical MPR as dependent variables, respectively. Odds ratios and 95% CIs were calculated for age, sex, race/ethnicity, MMAS-4 score, Charlson comorbidity score, depression scores from the 2-Item and the 9-Item Patient Health Questionnaires, health literacy, education, income, marital status, and randomization group. To asses if MINT modified adherence differentially among patients at risk for nonadherence, an interaction term was included between the randomized arm and the variables predictive of adherence. If any interactions were found to be significant, then the analyses were performed within the appropriate subgroups.
Results
Sample Characteristics
The sample (N = 452) was composed of 56% African American and 44% Hispanic patients. The mean age was 69.5 T 9 years, 58% were males, 56% had an spouse or partner, 22% had an education of high school or above, 40% had low health literacy, 46% had diabetes, 16% had depressive symptoms, and 13% presented with an acute myocardial infarction. Of the 452 participants, 227 received MINT and 225 the educational DVD. There were no statistically significant differences in the prevalence of baseline characteristics or predictors of adherence by randomization group, with the exception of annual income. A lower proportion of patients in the DVD group had an annual income less than $30 000 (74% vs 82%, P = .04) ( Table 1) . When evaluating the baseline characteristics by gender and race/ethnicity groups, African American and Hispanic women were more likely to have an annual income lower than $30 000 and to have low health literacy. African American women were less likely to be married or have a domestic partner and Hispanic women were more likely to have a positive screening for depressive symptoms (Table 2) .
Adherence to Antiplatelet Medication
When evaluating the prevalence of adequate and inadequate adherence to antiplatelet medications by baseline characteristics, we found that 57% of the entire sample were adequately adherent to their antiplatelet medication (64% among MINT vs 50% of DVD, P G .01). There were no differences in the prevalence of adequate adherence based on gender (58% in both groups P = .78) or race/ethnicity (Hispanic, 58% vs African American, 57%, P = .72). The prevalence of adequate adherence was statistically higher among those with a domestic partner and those who received MINT (P G .05). There was a higher prevalence of inadequate adherence among those with a positive screening for depression (56%) as well as among those participants with moderate to severe depressive symptoms (61%) (P G .01) ( Table 3) . 
Multivariate Predictors of Adherence
In multivariate analyses, patients with adequate selfreported adherence at baseline had higher odds of adequate 12-month adherence to antiplatelet medications. Those who had depressive symptoms had half the odds (adjusted odds ratio [AOR], 0.48; 95% CI, 0.27Y0.90; P = .02) of their nondepressed counterparts to have adequate medication adherence (MPR Q 0.80). Those with a higher Charlson comorbidity score had lower odds of adequate medication adherence when compared with patients with a lower Charlson comorbidity score (AOR, 0.89; 95% CI, 0.80Y0.98; P = .03). The more proficient a patient was in the English language, higher the odds of adequate medication adherence when compared with those with a lower proficiency in the English language (AOR, 1.9; 95% CI, 0.98Y3.9; P = .05). Patients who had a spouse or domestic partner had higher odds than unmarried patients to present with adequate medication adherence (AOR, 1.5; 95% CI, 0.99Y2.4; P = .05). Patients randomized to MINT had 3.5 higher odds of adequate medication adherence than those randomized to DVD (AOR, 3.5; 95% CI, 1.9Y2.7; P G .01) ( Table 4) . Health literacy did not significantly predict adequate medication adherence (AOR, 1.7; 95% CI, 0.93Y3.1; P = .28); however, in models that used the continuous MPR as an outcome, the less trouble patients had understanding written information, the higher the odds of adequate adherence (AOR, 2.9; 95% CI, 1.3Y6.3). Income, education, access to care, beliefs about the medication, and patient-physician communication did not predict adherence in either type of adjusted models. In evaluating if the MINT intervention effect varied according to other covariates associated with adherence, we found that the interaction terms between each of the variables and the randomized arm were not significant (all P values 9 .10), and in the stratified analyses, the odds ratios for the MINT intervention were similar.
Discussion
A number of easily measureable baseline characteristics were identified to predict 12-month adherence to antiplatelet medications among insured minority patients who received a coronary stent. Among these were baseline self-reported adherence, positive screening for depressive symptoms, moderate to severe depressive symptoms, and burden of disease. Low English proficiency, not having domestic partner, and health literacy might also influence adherence. The MINT intervention improved medication adherence similarly among patients with and without these risk factors.
Others have also found that despite the importance of socioeconomic status and access to care as predictors of disparities on objective health outcomes, these factors alone have not predicted medication adherence. 31Y34 This suggests that the health behaviors related to adherence with therapy are much more complex and involve multiple coexisting determinants that are difficult to tease apart. 8, 35 This poses a challenge for improving adherence to any medication, a task that becomes pivotal for medications known to improve survival such as antiplatelet medications post PCI. Nevertheless, in recent years, we have found that directive, patient-centered approaches such as motivational interviewing improve medication adherence to chronic medications. 7 Reasons for the improvement are not fully elucidated but may be related to motivational interviewing"s focus on eliciting the desire for change from within each individual and improving their autonomy and problem-solving skills. 36, 37 However, many of the medication adherence interventions shown effective in RCTs have been found to be unsustainable in real-world settings. 17 In this context, identifying replicable predictors of nonadherence can facilitate the dissemination of successful strategies. We identified a few clear predictors of adherence that have been previously linked to other outcomes. In particular, burden of disease and depression seem to be predictive of adverse events such as diabetes complications and mortality, 38 as well as mortality for congestive heart failure 39 and coronary artery disease. 40 However, the literature has been mixed regarding the association between adherence to medications and depressive symptoms, and it seems to vary according to disease state. Nevertheless, depression has been a consistent predictor of adherence among diabetic patients 35 and more recently among patients hospitalized with acute cardiac events. 41 The mechanisms by which subclinical and clinical depression influences outcomes are not fully understood but theories include poor self-management, hopelessness, as well as inflammatory mechanisms. 40 ,42Y44 However, studies have failed to demonstrate that reducing depressive symptoms improve clinical outcomes and recommend continuing the search for the mediating pathways. 38, 45 Our study suggests that MINT can improve adherence among patients with depressive symptoms without targeting depression per se but rather their self-management skills. In addition to the clinical risk factors, we found that early self-reported adherence measured by the 4-item Morisky score within 90 days of the stent placement is highly predictive of 12-month MPR.
Low health literacy, although previously found to be a mediator of adverse outcomes 46 and of self-reported adherence, 41 was not significant in multivariate models that used a categorical objective measure of adherence. This may suggest a confounding effect with the other factors or lack of discriminatory ability when using a dichotomized MPR because the health literacy effect was significant when the continuous MPR measure was used. The evidence to date supports its measurement for screening purposes.
In light of these findings, we propose the development and testing of a targeting strategy to be deployed at the time of PCI. This targeting strategy should include patients with moderate or severe depressive symptoms, low English proficiency, low health literacy, and more than 2 comorbidities from the Charlson score or those living alone. We could test adherence behaviors by collecting self-reported adherence (MMAS) for other cardiovascular medications at the time of PCI (eg, statin or hypertension). Patients who are experiencing lack of social support or poor self-management resources could benefit from a telephone-based, nurseled MINT post-PCI as demonstrated by the original RCT and this study. Collecting self-reported adherence to the antiplatelet medication between 30 and 90 days post-PCI or even later could be used to expand the identification of those at risk. Self-reported adherence correlates well to the objective MPR for antiplatelet medications among PCI recipients. 7 Given that changes in lifestyle related to having the PCI may affect mental health, we suggest retaking the 2-item or the 9-item Patient Health Questionnaire-2 during the follow-up visit or call between 30 and 90 days post-PCI. This is a more informed and equitable approach than selecting the use of a bare metal stent based on perceptions of potential barriers to adherence to antiplatelet medications such as insurance type, 47 race, 12 or other subjective information. There are several study limitations. First, the RCT included only African American and Hispanic patients insured mostly through Medicare to 1 single US health insurance organization. This may limit the generalizability of our results and of our proposed targeting strategy. Second, our population had a very low income and educational level, which may limit our ability to discern the impact of these sociodemographic variables.
Strengths include the prospective design, the low attrition rate at the end of the follow-up period, the use of an objective claims-based measure of adherence, the collection of self-reported instead of census-based SES and educational variables, as well as the collection of many of the previously reported determinants of adherence.
Conclusion
In conclusion, our study suggests that there are predictors that can be measured at the time of stent placement to inform PCI therapy and deployment of services to support medication adherence. Motivational interviewing was effective at improving adherence among patients with the identified risk factors. The cost-effectiveness of using this predictive model as a screening tool for risk of nonadherence to antiplatelet medications at the time of coronary stent placement needs to be evaluated among diverse populations in real-world settings.
What"s New and Important h Among insured minority patients who received a coronary stent, baseline self-reported adherence, positive screening for depression, and burden of disease predicted 12-month adherence to antiplatelet medications. h There are predictors that can be measured at the time of stent placement to inform PCI therapy and deployment of services to support medication adherence. h Motivational interviewing delivered by trained nurses is effective at improving adherence among patients with the identified risk factors.
